Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease

Erik S. Musiek has received research funding from Eisai Pharmaceuticals for preclinical work on sleep that is unrelated to lecanemab or any other antibody therapy, and was approved through a sponsored research agreement with Washington University. Erik S. Musiek has received no personal income related to this topic and has no financial stake in these companies. Eric McDade receives research funding from Eisai Pharmaceuticals for Clinical Trials in the Dominantly Inherited Alzheimer Network Trials Unit testing lecanemab and E2814; he has co-authored a recent publication with Eisai employees based on lecanemab phase II data and has presented data from the phase II studies at a scientific conference. Eric McDade has received research funding form Eli Lilly and Roche-Genentech for Clinical Trials in the Dominantly Inherited Alzheimer Network Trials Unit testing solanezumab and gantenerumab. He has received no personal income related to these activities and has no financial stake in these companies. David M. Holtzman is on the scientific advisory board of C2N diagnostics and has equity. David M. Holtzman is on the scientific advisory board of Denali Therapeutics, Genentech, and Cajal Therapeutics, and consults for Alector.